At-home gut microbiome tests are trending, selling insights to the curious, empowerment to the chronically ill and a claimed ...

Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting investor concerns about profitability and future growth levers. Management ...

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

A new, comprehensive market intelligence report from Credence Research indicates a period of sustained and significant growth ...

Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...

BLS revenue reached $799 million, up 8.3%, and adjusted operating income grew to $132 million. The quarter ended with an $8.6 billion backlog, and the BLS book-to-bill was 0.89 for the quarter and ...

Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion ...

Total revenues for the three months ended Sept. 30 were $3.56 billion, up from $3.28 billion in the third quarter of 2024 and matching the consensus Wall Street estimate.

Margin for the quarter improved 100 basis points, driven by Diagnostics. Adjusted EPS grew 19%, and we generated strong free ...

Labcorp boosted its 2025 adjusted per-share earnings target to a range between $16.15 and $16.50 a share from a prior projection of $16.05 to $16.50. The diagnostic testing company cut its revenue ...